CanSino Biologics (HKG:6185, SHA:688185) obtained approval to conduct a phase I clinical trial of its inhaled tuberculosis vaccine from Indonesia's drug regulator, a Thursday Hong Kong bourse filing said.
The study will investigate the safety and immunogenicity of a single dose of the vaccine in adults aged 18 to 49 years, the filing said.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。